Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

McGill University

$27,000.00

Investigating Hydroxocobalamin Dose-Response in Patient-Derived Cobalamin C Fibroblasts

FY 2025-26

Summary
Vitamin B12 is an essential nutrient that supports brain function, development, and red blood cell formation. However, the Vitamin B12 we consume must first be converted into active forms before the body can use it. Several proteins are required to process Vitamin B12, one of which is encoded by the MMACHC gene. Mutations in MMACHC cause cobalamin C disorder (cblC), a serious genetic condition in which the body cannot activate Vitamin B12, leading to widespread metabolic complications such as developmental delays, anemia, seizures, and vision loss. Despite defective Vitamin B12 processing, cblC patients respond well to hydroxycobalamin (OHCbl), an injectable form of Vitamin B12. Recent studies suggest that very high OHCbl doses may lead to better outcomes compared to the standard treatment. However, the optimal dose is unknown, and there are no formal dosing guidelines. This project aims to determine the optimal dose of OHCbl needed to achieve the best treatment outcomes. To do this, I will culture skin cells (fibroblasts) donated from individuals with cblC and healthy controls. I will then measure how different OHCbl doses affect an important Vitamin B12-dependent reaction inside the cell. Based on these results, I will determine the OHCbl concentration required to correct the biochemical defect in cblC cells. Subsequently, I will compare these laboratory findings with OHCbl levels seen in patients receiving high-dose OHCbl treatment. If the doses overlap, this will support clinical practice and guide dosing recommendations. If they do not, then additional physiological factors absent in fibroblast models may need to be investigated. Ultimately, defining the optimal OHCbl dose range will reduce treatment variability and improve long-term outcomes for cblC patients.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572771
Name
Metwally Raghd
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating Hydroxocobalamin Dose-Response in Patient-Derived Cobalamin C Fibroblasts
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cobalamin; Cobalamin C Disorder; Dose Escalation; Homocysteine; Inborn Errors Of Metabolism; Mmachc; Patient-Derived Fibroblasts; Somatic Cell Genetics; Vitamin B12; [14]-Methyltetrahydrofolate Incorporation
Abstract
Vitamin B12 is an essential nutrient that supports brain function, development, and red blood cell formation. However, the Vitamin B12 we consume must first be converted into active forms before the body can use it. Several proteins are required to process Vitamin B12, one of which is encoded by the MMACHC gene. Mutations in MMACHC cause cobalamin C disorder (cblC), a serious genetic condition in which the body cannot activate Vitamin B12, leading to widespread metabolic complications such as developmental delays, anemia, seizures, and vision loss. Despite defective Vitamin B12 processing, cblC patients respond well to hydroxycobalamin (OHCbl), an injectable form of Vitamin B12. Recent studies suggest that very high OHCbl doses may lead to better outcomes compared to the standard treatment. However, the optimal dose is unknown, and there are no formal dosing guidelines. This project aims to determine the optimal dose of OHCbl needed to achieve the best treatment outcomes. To do this, I will culture skin cells (fibroblasts) donated from individuals with cblC and healthy controls. I will then measure how different OHCbl doses affect an important Vitamin B12-dependent reaction inside the cell. Based on these results, I will determine the OHCbl concentration required to correct the biochemical defect in cblC cells. Subsequently, I will compare these laboratory findings with OHCbl levels seen in patients receiving high-dose OHCbl treatment. If the doses overlap, this will support clinical practice and guide dosing recommendations. If they do not, then additional physiological factors absent in fibroblast models may need to be investigated. Ultimately, defining the optimal OHCbl dose range will reduce treatment variability and improve long-term outcomes for cblC patients.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Metwally, Raghd
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~